Skip to main content

Table 1 Clinical features of the 33 temporal lobe epilepsy patients with amygdala enlargement

From: Temporal lobe epilepsy with amygdala enlargement: a subtype of temporal lobe epilepsy

Patient Number

Age at scan (years)

Gender

Onset age (years)

Seizure type

EEG

Imaging

SGTC time

CPS frequency

Emotioal disorder

AEDs

1

27

F

20

CPS SGTC

L

L

Sleep

1-2/year

Depression, anxiety

CBZ 400 mg/d

2

25

F

23

CPS

R

R

 

3-5/month

Depression, anxiety

CBZ 400 mg/d

3

28

M

26

CPS

R

R

 

2/month

Depression, anxiety

OXC 600 mg/d

4

66

M

61

CPS

L

L

 

2-4/month

Anxiety

LEV 1000 mg/d OXC 600 mg/d

5

36

F

34

SPS CPS SGTC

L

L

Sleep

3/month

Depression, anxiety

CBZ 400 mg/d

6

22

M

20

SGTC

R

R

Sleep

3-6/month

Depression, anxiety

CBZ 600 mg/d

7

77

F

75

CPS

L

L

 

4/month

Dementia

CBZ 300 mg/d

8

41

F

40

CPS

L

L

 

3-6/month

Depression

CBZ 400 mg/d

9

60

M

50

CPS SGTC

R

R

Sleep

3-8/month

Depression, anxiety

LEV 1000 mg/d OXC 400 mg/d

10

49

F

48

CPS

L

L

 

5/month

Depression, anxiety

CBZ 400 mg/d

11

59

M

57

CPS

R

R

 

1/month

Depression, anxiety

CBZ 600 mg/d

12

52

F

50

CPS SGTC

B

B

Awake

4-5/month

Depression, anxiety

CBZ 400 mg/d

13

51

F

45

CPS

L

L

 

7/month

Depression, anxiety

LEV 1000 mg/d CBZ 600 mg/d

14

56

M

55

SPS CPS SGTC

L

L

Awake

3-5/month

Dementia, memory decrease

CBZ 600 mg/d

15

44

M

43

CPS

L

L

 

3-7/month

Depression, anxiety

CBZ 400 mg/d

16

48

F

43

CPS

B

B

 

8/month

Memory decrease, bipolar disorder

LEV 1000 mg/d CBZ 600 mg/d

17

61

F

57

SPS SGTC

R

R

Sleep

3-7/month

Depression

OXC 1200 mg/d

18

40

M

39

CPS SGTC

L

L

Awake

7/month

Depression, Anxiety, memory decrease

CBZ 600 mg/d

19

56

M

55

CPS SGTC

L

L

Sleep

3/month

Depression, Anxiety, memory decrease

CBZ 600 mg/d

20

31

M

30

CPS SGTC

L

L

Sleep

3-6/month

Depression, anxiety

OXC 900 mg/d

21

69

M

68

CPS SGTC

R

R

Sleep

5/month

Depression, anxiety

CBZ 400 mg/d

22

51

F

49

SPS CPS

R

R

 

6/month

Anxiety, depression, memory decrease

LEV 1000 mg/d CBZ 600 mg/d

23

36

F

34

SPS CPS

R

R

 

3-4/month

Anxiety, aggression

LEV 1000 mg/d CBZ 600 mg/d

24

41

F

40

CPS SGTC

R

R

Awake

3-6/month

Anxiety, memory decrease

OXC 900 mg/d

25

60

M

59

CPS

R

R

 

3-7/month

Depression, anxiety

CBZ 600 mg/d

26

24

F

22

CPS

L

L

 

3/month

Depression, anxiety

OXC 900 mg/d

27

40

F

37

CPS

R

R

 

5/month

Depression, anxiety

LEV 1000 mg/d CBZ 600 mg/d

28

35

M

24

CPS SGTC

L

L

Sleep

2-3/month

Depression, anxiety

LEV 1000 mg/d CBZ 800 mg/d

29

35

M

34

CPS

R

R

 

3-8/month

Depression, anxiety, personality change

CBZ 800 mg/d

30

38

F

36

SPS CPS

R

R

 

3-6/month

Anxiety, depression, aggression

LEV 1000 mg/d CBZ 600 mg/d

31

51

M

49

CPS

R

R

 

7/month

Depression, anxiety, memory decrease

LEV 1000 mg/d CBZ 600 mg/d

32

41

M

39

CPS

L

L

 

3-5/month

Depression, anxiety, memory decrease

CBZ 800 mg/d

33

35

F

23

CPS SGTC

L

L

Sleep

3-7/month

Depression, memory decrease, bipolar disorder

LEV 1000 mg/d CBZ 800 mg/d

  1. Patient age at time of 3.0 T MRI examination. Mean age was 45.0 years (SD 13.9).
  2. Imaging studies consisted of interictal FDG-PET (fluorodeoxyglucose-positron emission tomography).
  3. F female, M male, R right, L left, B bilateral, SPS simple partial seizure, CPS complex partial seizure, SGTC secondary generalized tonic-clonic seizure, AEDs antiepileptic drugs, CBZ carbamazepine, OXC Oxcarbazepine, LEV Levetiracetam, d day.